The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

[1]  D. S. Gross,et al.  Chromatin , 2020, Definitions.

[2]  Robin Talbot,et al.  Analysis and interpretation of data , 2014 .

[3]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[4]  J. Chen,et al.  A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants , 2013, PloS one.

[5]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[6]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[7]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[8]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[9]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[10]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[11]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[12]  Howard Y. Chang,et al.  Chromatin Isolation by RNA Purification (ChIRP) , 2012, Journal of visualized experiments : JoVE.

[13]  Tatiana A. Tatusova,et al.  NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy , 2011, Nucleic Acids Res..

[14]  Emily A. Vucic,et al.  Human Cancer Long Non-Coding RNA Transcriptomes , 2011, PloS one.

[15]  Olivier Elemento,et al.  An integrated ChIP-seq analysis platform with customizable workflows , 2011, BMC Bioinformatics.

[16]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[17]  Howard Y. Chang,et al.  A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression , 2011, Nature.

[18]  S. Nakagawa,et al.  Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice , 2011, The Journal of cell biology.

[19]  M. Rubin,et al.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. , 2010, Neoplasia.

[20]  John S. Mattick,et al.  lncRNAdb: a reference database for long noncoding RNAs , 2010, Nucleic Acids Res..

[21]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[22]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[23]  D. Chakravarty,et al.  PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor‐α target gene activation by regulating lysine demethylase 1 specificity , 2010, EMBO reports.

[24]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[25]  Luzhe Sun,et al.  Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. , 2010, Cancer research.

[26]  Stephan H. Bernhart,et al.  RNPomics: Defining the ncRNA transcriptome by cDNA library generation from ribonucleo-protein particles , 2010, Nucleic acids research.

[27]  C. Evelo,et al.  Identification of novel ER-α target genes in breast cancer cells: Gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17β-estradiol and tamoxifen , 2010, Molecular and Cellular Endocrinology.

[28]  Sarah L Vowler,et al.  Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. , 2010, Genes & development.

[29]  B. Leyland-Jones,et al.  Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts , 2010, British Journal of Cancer.

[30]  Manoj Bhasin,et al.  Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer , 2009, Clinical Cancer Research.

[31]  C. Bond,et al.  Paraspeckles: nuclear bodies built on long noncoding RNA , 2009, The Journal of cell biology.

[32]  T. Borodina,et al.  Transcriptome analysis by strand-specific sequencing of complementary DNA , 2009, Nucleic acids research.

[33]  J. Rinn,et al.  Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression , 2009, Proceedings of the National Academy of Sciences.

[34]  John N. Hutchinson,et al.  An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. , 2009, Molecular cell.

[35]  Michael F. Lin,et al.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals , 2009, Nature.

[36]  R. Broaddus,et al.  Role of PELP1/MNAR signaling in ovarian tumorigenesis. , 2008, Cancer research.

[37]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[38]  Yuzhuo Wang,et al.  Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  P. Singh,et al.  A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. , 2008, European journal of cancer.

[40]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[41]  Taishin Kin,et al.  Identification and characterization of human non-coding RNAs with tissue-specific expression. , 2007, Biochemical and biophysical research communications.

[42]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[43]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[44]  Pengbo Liu,et al.  Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.

[45]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[46]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[47]  Emily Bernstein,et al.  RNA meets chromatin. , 2005, Genes & development.

[48]  Peter F Stadler,et al.  Fast and reliable prediction of noncoding RNAs , 2005, Proc. Natl. Acad. Sci. USA.

[49]  Allen Chong,et al.  Discovery of estrogen receptor α target genes and response elements in breast tumor cells , 2004, Genome Biology.

[50]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[52]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[55]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[56]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[57]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[58]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[59]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[60]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[61]  H. Bonkhoff,et al.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. , 1999, The American journal of pathology.

[62]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[63]  V. Adam,et al.  Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. , 2012, Neoplasma.

[64]  Francesca Demichelis,et al.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. , 2011, Genome research.

[65]  G. Sonpavde.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[66]  Ira M. Hall,et al.  BEDTools: a flexible suite of utilities for comparing genomic features , 2010, Bioinform..

[67]  G. Cancel-Tassin,et al.  Association between estrogen and androgen receptor genes and prostate cancer risk. , 2009, European journal of endocrinology.

[68]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[69]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[70]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[71]  E. Bergstralh,et al.  Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.

[72]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[73]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[74]  Mark Gerstein,et al.  Bioinformatics Applications Note Gene Expression Rseqtools: a Modular Framework to Analyze Rna-seq Data Using Compact, Anonymized Data Summaries , 2022 .